Corcept Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue grew 32% year-over-year to $256.1 million, driven by strong launches in both endocrinology and oncology. LIFYORLI saw rapid uptake with over 1,300 patients treated, and guidance was raised to $1.1–$1.2 billion for 2026.
-
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Fiscal Year 2025
-
Revenue grew 13% to $761M in 2025, driven by record Cushing's syndrome demand, while net income declined. Regulatory and legal setbacks impacted relacorilant, but strong clinical data and pharmacy transition support future growth.
-
Q3 2025 revenue rose 14% year-over-year to $207.6M, with strong hypercortisolism growth and expanded prescriber base. Net income declined, but cash remains robust after $50M in stock buybacks. Multiple late-stage clinical programs are advancing, with Relacorilant FDA decisions expected in 2025 and 2026.
-
Q2 2025 revenue rose 19% year-over-year to $194.4 million, driven by record prescription growth and expanding market awareness. Relacorilant is expected to replace Korlym and drive multi-billion dollar annual sales, with key regulatory decisions and expanded pharmacy capacity anticipated by year-end.
-
Revenue grew 7% year-over-year to $157.2 million in Q1 2025, with strong patient and prescriber growth driven by increased hypercortisolism screening and Korlym demand. Relacorilant's NDA is under FDA review, and positive oncology trial results support future expansion.
Fiscal Year 2024
-
2024 saw 40% revenue growth and record Korlym adoption, with strong cash reserves and a positive outlook. NDA for relacorilant is under FDA review, pivotal ROSELLA results are imminent, and the addressable market is expanding rapidly.
-
Q3 2024 revenue grew 48% year-over-year to $182.5 million, with net income at $47.2 million and cash of $547.6 million. Raised 2024 revenue guidance to $675–$700 million, driven by strong Korlym performance and positive relacorilant phase III results supporting an NDA submission.
-
Q2 2024 revenue grew 39% year-over-year to $163.8 million, with net income rising to $35.5 million. Raised 2024 revenue guidance to $640–$670 million, driven by strong commercial performance and clinical milestones, including positive GRACE trial results and expanded market awareness.